Abstract
Get full access to this article
View all access options for this article.
References
1.
Fernandez-Lopez S
,
Kazzaz D
,
Bashir M
,
McLaughlin T.
Assessment of pharmacists’ views on biosimilar naming conventions . J Manag Care Spec Pharm. 2015 ;21 (3 ):188 –195 .
2.
Chandra A
,
Vanderpuye-Orgle J.
Competition in the age of biosimilars . JAMA . 2015 ;314 (3 ):225 –226 .
3.
Nonproprietary naming of biological products guidance for industry. FDA Web site. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM459987.pdf. Published April 2015 . Accessed August 28 , 2015 .
4.US Food and Drug Administration . Nonproprietary naming of biological products. Draft guidance for industry; availability. https://www.federalregister.gov/articles/2015/08/28/2015-21383/nonproprietary-naming-of-biological-products-draft-guidancefor-industry-availability. Published August 28, 2015 . Accessed September 4 , 2015 .
5.
The NOR-SWITCH study. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02148640. Updated April 2015 . Accessed September 3 , 2015 .
6.
Stanton D.
Norway to facilitate switch to biosimilars with $3m Remicade study. BioPharma-Reporter . http://www.biopharma-reporter.com/Markets-Regulations/Norwayto-facilitate-switch-to-biosimilars-with-3m-Remicadestudy. Published December 6, 2013 . Accessed September 3 , 2015 .
7.
Feldman SR
. Inflammatory diseases: Integrating biosimilars into clinical practice . Semin Arthritis Rheum. 2015 ;44 (6 suppl ):S16 –S21 .